p53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer.

p53R2 is a small subunit of ribonucleotide reductase (RR) which has 80% homology to hRRM2 and metastasis-suppressing potential. Previous reports suggested that the expression of p53R2 is used as a prognostic factor and chemotherapy response indicator in several types of cancer. This study aimed to elucidate the association of p53R2 expression and the clinicopathological characteristics of early stage non-small cell lung cancer (NSCLC). Immunohistochemistry was conducted on a tissue array including 92 early stage NSCLC samples. Correlations between p53R2 and clinicopathological factors, recurrence/metastasis and outcomes were analyzed. The analyses showed that there was no correlation between p53R2 expression and the clinicopathological factors. Among disease-free patients during follow-up, patients with p53R2(+) had a better outcome than those with p53R2(-) (P=0.022). By using Cox multivariate regression analysis, p53R2 (risk factor 3.801; 95% CI 1.004-9.454; P=0.044) served as a prognostic biomarker in the prediction of the survival rate for NSCLC patients. Detection of the RR subunit p53R2 may therefore be a useful prognostic marker in early stage NSCLC.

[1]  Kounosuke Watabe,et al.  Metabolic genes in cancer: their roles in tumor progression and clinical implications. , 2010, Biochimica et biophysica acta.

[2]  A. Mizuno,et al.  Ribonucleotide reductase small subunit p53R2 promotes oral cancer invasion via the E-cadherin/beta-catenin pathway. , 2009, Oral oncology.

[3]  H. You,et al.  Ribonucleotide reductase small subunit p53R2 suppresses MEK–ERK activity by binding to ERK kinase 2 , 2009, Oncogene.

[4]  David A Jones,et al.  p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. , 2008, Cancer research.

[5]  R. Bronson,et al.  Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms. , 2008, Cancer research.

[6]  Lijun Xue,et al.  Metastasis-Suppressing Potential of Ribonucleotide Reductase Small Subunit p53R2 in Human Cancer Cells , 2006, Clinical Cancer Research.

[7]  S. Natsugoe,et al.  Expression of p53R2 Is Related to Prognosis in Patients with Esophageal Squamous Cell Carcinoma , 2006, Clinical Cancer Research.

[8]  T. Oyama,et al.  P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer. , 2006, Anticancer research.

[9]  Nuno M F S A Cerqueira,et al.  Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy. , 2005, Current medicinal chemistry.

[10]  Yate-Ching Yuan,et al.  In Vitro Characterization of Enzymatic Properties and Inhibition of the p53R2 Subunit of Human Ribonucleotide Reductase , 2004, Cancer Research.

[11]  P. Reichard.  Ribonucleotide reductases: the evolution of allosteric regulation. , 2002, Archives of biochemistry and biophysics.

[12]  Yusuke Nakamura,et al.  Mammalian p53R2 Protein Forms an Active Ribonucleotide Reductasein Vitro with the R1 Protein, Which Is Expressed Both in Resting Cells in Response to DNA Damage and in Proliferating Cells* , 2001, The Journal of Biological Chemistry.

[13]  Yusuke Nakamura,et al.  A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage , 2000, Nature.

[14]  Yun Yen,et al.  Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential , 1998, Clinical & Experimental Metastasis.

[15]  J. Wright,et al.  The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[17]  J. Wright,et al.  Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Lijun Xue,et al.  Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. , 2007, Clinical colorectal cancer.